about
Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children.International network for comparison of HIV neutralization assays: the NeutNet report.Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4.In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescentAutomated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition.Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms.Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.HIV-1 co-receptor usage: influence on mother-to-child transmission and pediatric infectionTherapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC)HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets.Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus MacaquesOral CCR5 inhibitors: will they make it through?Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolateSuperior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.Phenotype variation in human immunodeficiency virus type 1 transmission and disease progressionHIV-1 infection: the role of the gastrointestinal tract.Modified Vaccinia Virus Ankara Vector Induces Specific Cellular and Humoral Responses in the Female Reproductive Tract, the Main HIV Portal of Entry.HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights.Determination of HIV-1 co-receptor usage.Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial.Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes.HLA-C is necessary for optimal human immunodeficiency virus type 1 infection of human peripheral blood CD4 lymphocytes.Biological and genetic evolution of HIV type 1 in two siblings with different patterns of disease progression.Occupational HIV Infection in a Research Laboratory With Unknown Mode of Transmission: A Case Report.Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.HIV type 1 chemokine receptor usage in mother-to-child transmission.Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype.Immunization with clinical HIV-1 Env proteins induces broad antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies in a rabbit vaccination model.Intradermal HIV-1 DNA immunization using needle-free Zetajet<sup>TM</sup> injection followed by HIV-modified vaccinia virus Ankara vaccination is safe and immunogenic in Mozambican young adults: a phase I randomized controlled trial.Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells.HIV-1 isolation from infected peripheral blood mononuclear cells.B-cell subset alterations and correlated factors in HIV-1 infection.Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011.Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaoundé, Cameroon.
P50
Q27666159-CE0A9D3D-54E2-40D8-8C67-641D6F7F0425Q33372329-6FE7B3DF-3811-4B98-8BF1-BA0E4AC1239DQ33410826-E8F8727E-F858-4273-979F-8D7BD5392F4BQ33955745-C6C46679-4C99-4CB6-91DE-3CD50907D3A0Q33983104-7BE53588-AADF-4609-AEEF-DBF41D88F1D1Q34445208-FF90B181-7F73-4717-ACBE-C585E757F300Q34606488-3D3E3FB7-2B69-4A89-8F0E-99D0688F7C8AQ34667609-D20A5511-1F2B-4E32-AD21-56027CC8FC4DQ34746588-DB187825-5455-4070-A4A6-05C733B1B24FQ34984724-A3362898-EB35-4601-A854-AA22EA408422Q35018123-7A80DBE7-882F-4CE1-9221-989F75B8EC52Q35060232-6AEDFE2B-FD09-480F-89AA-3B4309B18D32Q35677513-4E134A45-2AEA-4608-8B9A-9F5FD28CEF01Q35810521-EABFEA53-92B7-4543-B6B1-F551F37F049BQ35826692-EAEAB506-FD0D-48E2-9B56-52C06A08FA4EQ36458354-A1045408-835D-4494-AE3F-2A66F1E06AA4Q37060319-3D2964D5-3C67-4483-9BFA-C0F19B268E41Q37069793-2D44B44F-7C45-4389-A8AD-C475A97D0DA7Q37628364-0C1E0EAE-D5E3-48ED-9FFB-9646E7B521CBQ38201117-0F72ADF7-55D6-4203-961C-4590B17B742DQ38369341-A5D567E1-E519-44F3-968F-01E13F4815FDQ38666772-AD60F4BC-3AC5-451D-B816-AC43027DF8AEQ39070650-B3411EC1-3091-4857-B058-7600E5A6B825Q39399731-075D4C27-5189-44B8-A857-9C358054296EQ39632891-9829BD7B-2FFA-4C27-8222-ECD411449424Q39795932-FC0D19FB-1EAE-4499-A45E-0067594AC4F3Q40030892-3B64265E-B58B-4DEC-9F24-A5C2947662F3Q40390935-E79D1F06-29FC-49FD-B2EF-2144514A712DQ40393896-B858797E-E516-48BC-9482-5D2A2D70338EQ40791491-6841D6D0-E1CB-4FBE-B0D8-1CF565F6F907Q41511107-2EFE3A1C-8033-48DB-9008-A496F10523D8Q41923481-51EFAE21-F8BA-42DF-8053-724A8511BB52Q41926279-2E2C50B3-2F56-4D23-93B1-CBE25D14111DQ42167549-2718363A-57A3-412B-B38A-1E004B24CE2BQ42172842-EF73CA6D-529D-49EC-A429-98BF61E12C79Q42259833-80805470-A524-4FB7-9CDE-DE4D3EAB369DQ42277808-FB0CE9EB-FBCC-4C19-8ABC-A325E9E02A70Q42411962-EBC5DDE7-340E-4713-89DD-866D15744C6EQ42726161-DC514EA8-382D-4173-8EA4-34F73823D01CQ44644328-7311E2E4-6E5D-406C-BE57-A7FFC344FA7A
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gabriella Scarlatti
@ast
Gabriella Scarlatti
@en
Gabriella Scarlatti
@es
Gabriella Scarlatti
@nl
type
label
Gabriella Scarlatti
@ast
Gabriella Scarlatti
@en
Gabriella Scarlatti
@es
Gabriella Scarlatti
@nl
prefLabel
Gabriella Scarlatti
@ast
Gabriella Scarlatti
@en
Gabriella Scarlatti
@es
Gabriella Scarlatti
@nl
P106
P21
P31
P496
0000-0003-2316-2689